Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

Plain-language summary

This study investigates the effect of the drug Thalidomide at different doses in patients with transfusion-dependent beta thalassemia. It enrolls patients diagnosed with transfusion-dependent beta thalassemia major or intermedia who provide informed consent. It is being conducted in Phase 2 and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Recruiting

Sponsor

National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

Intervention

Thalidomide, Thalidomide

Start date

4/22/2024

Estimated completion

4/22/2026

Countries

Pakistan

Related genes

Locations

• Karachi, Pakistan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Know case of beta thalassemia major/ intermediate ( transfusion dependent)
* willing to give informed consent

Exclusion Criteria:

* Patients with comorbidities such as liver dysfunction
* Married patients
* Lactating mother
* H/O thrombosis and fits